| ISIN | LU2050612402 |
|---|---|
| Valor Number | |
| Bloomberg Global ID | |
| Fund Name | JPMorgan Funds – Thematics - Genetic Therapies A (acc)-USD |
| Fund Provider |
J.P. Morgan Bank Luxembourg S.A.
6, route de Trèves L-2633, Senningerberg Grand Duchy of Luxembourg |
| Fund Provider | J.P. Morgan Bank Luxembourg S.A. |
| Representative in Switzerland |
JPMorgan Asset Management (Switzerland) LLC Genève Phone: +41 22 744 11 11 |
| Distributor(s) |
JP Morgan Asset Management (Europe) Sàrl Senningerberg Phone: +352 34 10 1 |
| Asset Class | Equities |
| EFC Category | |
| Distribution Policy | Accumulation |
| Home Country | Luxembourg |
| Issuing Condition | Combination of issuing commission charged by the fund management company and transaction fee charged by the fund |
| Redemption Condition | Combination of redemption commission charged by the fund management company and transaction fee charged by the fund |
| Investment Strategy *** | To achieve a return by investing in companies with exposure to the theme of genetic therapies, globally. |
| Peculiarities |
| Current Price * | 106.14 USD | 29.10.2025 |
|---|---|---|
| Previous Price * | 107.30 USD | 28.10.2025 |
| 52 Week High * | 107.89 USD | 16.10.2025 |
| 52 Week Low * | 72.17 USD | 09.04.2025 |
| NAV * | 106.14 USD | 29.10.2025 |
| Issue Price * | ||
| Redemption Price * | ||
| Closing Price * | ||
| Indicative Minimum Price | ||
| Fund Assets *** | 385,263,517 | |
| Unit/Share Assets *** | 105,261,081 | |
| Trading Information SIX | ||
| YTD Performance | +17.71% |
31.12.2024 - 29.10.2025
31.12.2024 29.10.2025 |
|---|---|---|
| YTD Performance (in CHF) | +2.88% |
31.12.2024 - 29.10.2025
31.12.2024 29.10.2025 |
| 1 month | +8.92% |
29.09.2025 - 29.10.2025
29.09.2025 29.10.2025 |
| 3 months | +17.96% |
29.07.2025 - 29.10.2025
29.07.2025 29.10.2025 |
| 6 months | +27.01% |
29.04.2025 - 29.10.2025
29.04.2025 29.10.2025 |
| 1 year | +5.74% |
29.10.2024 - 29.10.2025
29.10.2024 29.10.2025 |
| 2 years | +26.24% |
30.10.2023 - 29.10.2025
30.10.2023 29.10.2025 |
| 3 years | -2.36% |
31.10.2022 - 29.10.2025
31.10.2022 29.10.2025 |
| 5 years | -22.93% |
29.10.2020 - 29.10.2025
29.10.2020 29.10.2025 |
| Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI Date | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| uniQure NV | 3.90% | |
|---|---|---|
| Ionis Pharmaceuticals Inc | 3.40% | |
| CRISPR Therapeutics AG | 3.40% | |
| PTC Therapeutics Inc | 3.39% | |
| Wuxi AppTec Co Ltd | 3.09% | |
| Novartis AG Registered Shares | 3.02% | |
| Alnylam Pharmaceuticals Inc | 3.01% | |
| Gilead Sciences Inc | 2.82% | |
| Astellas Pharma Inc | 2.81% | |
| Krystal Biotech Inc | 2.72% | |
| Last data update | 30.09.2025 | |
| TER *** | 0.95% |
|---|---|
| TER date *** | 30.06.2025 |
| Performance Fee *** | |
| PTR | |
| Max. Management Fee *** | 0.72% |
| Ongoing Charges *** | 0.95% |
|
SRRI ***
|
|
| SRRI date *** | 30.09.2025 |